We are monitoring the impact of COVID-19 on MEA Lung Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Middle East & Africa Lung Cancer Therapeutics Market Research Report - Segmented By Treatment Type & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends & Forecast (2022 to 2027)

Published: January, 2022
ID: 838
Pages: 135

MEA Lung Cancer Therapeutics Market Size & Growth (2022 to 2027)

According to the report, The Middle-East and Africa Lung Cancer Therapeutics Market size was worth USD 0.76 billion in 2022 and estimated to be growing at a CAGR of 6.59%, to reach USD 1.04 billion by 2027.

Medical improvements have presented effective methods for the treatment of lung cancer. Presently, surgery, chemotherapy, and radiation therapy are foremost treatment possibilities implemented. Lung cancer is treated majorly with chemotherapy and radiation therapy. The primary lung carcinomas originate from epithelial cells.

The Middle-East and Africa lung cancer therapeutics market would be driven by growing acceptance of modified treatments. Though new drugs have restored the lung cancer therapeutics market, patent expiry of existing drugs has postured a major risk to original drug manufacturers.

Still, this has also shaped new chances for generic drug manufacturers to promote low-cost generic drugs.

This research report on the MEA Lung Cancer Therapeutics Market is segmented and sub-segmented into the following categories:

By Treatment Type:

  • Chemotherapy
    • Cisplatin
    • Taxol
    • Navelbine
    • Camptosar
    • Alimta
  • Radiotherapy
    • External Beam
    • Internal Beam
    • Systemic
  • Other Drugs
    • Abraxane
    • Avastin
    • Crizotinib
    • Docetaxel
    • Gefitinib

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Regionally, Middle-East is anticipated to witness high growth in the forecast period and Africa is expected to dominate the Middle-East and Africa region lung cancer therapeutics market.

The leading companies leading in the MEA Lung Cancer Therapeutics Market profiled in this report are Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstrazenecaPlc, and Sanofi-Aventis.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Treatment Type                                 

                                5.1.1 Chemotherapy                     

                                                5.1.1.1 Cisplatin

                                                5.1.1.2 Taxol      

                                                5.1.1.3 Navelbine            

                                                5.1.1.4 Camptosar          

                                                5.1.1.5 Alimta   

                                5.1.2 Radiotherapy                         

                                                5.1.2.1 External Beam   

                                                5.1.2.2 Internal Beam    

                                                5.1.2.3 Systemic              

                                5.1.3 Other Drugs                            

                                                5.1.3.1 Abraxane             

                                                5.1.3.2 Avastin 

                                                5.1.3.3 Crizotinib             

                                                5.1.3.4 Docetaxel            

                                                5.1.3.5 Gefitinib               

6. Geographical Analysis                                                              

                6.1 Introduction                                              

                6.2 Brazil                                             

                6.3 Mexico                                         

                6.4 Argentina                                    

                6.5 Rest of Latin America                                             

7. Pipeline Product Analysis                                                       

                7.1 Overview                                                    

                7.2 Pipeline Development Landscape                                                    

                7.3 Molecular Targets in the Pipeline                                                     

                7.4 Clinical Trials                                             

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target                       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                                  

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.                               

8. Strategic Analysis                                                       

                8.1 PESTLE analysis                                         

                                8.1.1 Political                     

                                8.1.2 Economic                 

                                8.1.3 Social                         

                                8.1.4 Technological                         

                                8.1.5 Legal                          

                                8.1.6 Environmental                      

                8.2 Porter’s Five analysis                                              

                                8.2.1 Bargaining Power of Suppliers                        

                                8.2.2 Bargaining Power of Consumers                    

                                8.2.3 Threat of New Entrants                     

                                8.2.4 Threat of Substitute Products and Services               

                                8.2.5 Competitive Rivalry within the Industry                      

9. Market Leaders' Analysis                                                        

                9.1 BoehringerIngelheim GmbH                               

                                9.1.1 Overview                

                                9.1.2 Product Analysis                   

                                9.1.3 Strategic Evaluation and Operations                            

                                9.1.4 Financial analysis                  

                                9.1.5 Legal issues                            

                                9.1.6 Recent Developments                       

                                9.1.7 SWOT analysis                       

                                9.1.8 Analyst View                          

                9.2 Hoffman-La Roche                                  

                9.3 Pfizer Inc.                                    

                9.4 GlaxoSmitKline                                         

                9.5 Eli Lilly and Company                                             

                9.6 AstrazenecaPlc                                         

                9.7 Sanofi-Aventis                                          

                9.8 Agennix AG                                

10. Competitive Landscape                                                         

                10.1 Market share analysis                                          

                10.2 Merger and Acquisition Analysis                                     

                10.3 Agreements, collaborations and Joint Ventures                                       

                10.4 New Product Launches                                       

11. Expert Opinions                                                        

                11.1 Market Outlook                                     

                11.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  1. Middle East & Africa Lung Cancer Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  2. Middle East & Africa Lung Cancer Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  3. Middle East & Africa Chemotherapy Market By Region, From 2022 - 2027 (USD Billion)
  4. Middle East & Africa Radiotherapy Market By Region, From 2022 - 2027 (USD Billion)
  5. Middle East & Africa Other Lung Cancer Therapeutic Drugs Market By Region, From 2022 - 2027 (USD Billion)
  6. Middle East Lung Cancer Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  7. Africa Lung Cancer Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  8. Middle East & Africa Lung Cancer Chemotherapy Market By Drug Type, From 2022 - 2027 (USD Billion)
  9. Middle East & Africa Cisplatin Market By Region, From 2022 - 2027 (USD Billion)
  10. Middle East & Africa Taxol Market By Region, From 2022 - 2027 (USD Billion)
  11. Middle East & Africa Navelbine Market By Region, From 2022 - 2027 (USD Billion)
  12. Middle East & Africa Camptosar Market By Region, From 2022 - 2027 (USD Billion)
  13. Middle East & Africa Alimta Market By Region, From 2022 - 2027 (USD Billion)
  14. Middle East Lung Cancer Chemotherapy Market By Drug Type, From 2022 - 2027 (USD Billion)
  15. Africa Lung Cancer Chemotherapy Market By Drug Type, From 2022 - 2027 (USD Billion)
  16. Middle East & Africa Lung Cancer Radiotherapy Market By Type, From 2022 - 2027 (USD Billion)
  17. Middle East & Africa External Beam Market By Region, From 2022 - 2027 (USD Billion)
  18. Middle East & Africa Internal Beam Market By Region, From 2022 - 2027 (USD Billion)
  19. Middle East & Africa Systemic Market By Region, From 2022 - 2027 (USD Billion)
  20. Middle East Lung Cancer Radiotherapy Market By Type, From 2022 - 2027 (USD Billion)
  21. Africa Lung Cancer Radiotherapy Market By Type, From 2022 - 2027 (USD Billion)
  22. Middle East & Africa Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2022 - 2027 (USD Billion)
  23. Middle East & Africa Abraxane Market By Region, From 2022 - 2027 (USD Billion)
  24. Middle East & Africa Avastin Market By Region, From 2022 - 2027 (USD Billion)
  25. Middle East & Africa Crizotinib Market By Region, From 2022 - 2027 (USD Billion)
  26. Middle East & Africa Docetaxel Market By Region, From 2022 - 2027 (USD Billion)
  27. Middle East & Africa Gefitinib Market By Region, From 2022 - 2027 (USD Billion)
  28. Middle East Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2022 - 2027 (USD Billion)
  29. Africa Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample